Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Presentation

Evolution of Blood-Brain Barrier Penetrant AAV Capsids in Non-Human Primates Using a Multiplexed Transcription Dependent Capsid Engineering Platform

Download PDF